Oscar Reig

Servei d'Oncologia Mèdica Oncòleg

Grup de recerca

Genòmica translacional i teràpies dirigides en tumors sòlids Accredited researcher (R3A)

oreig@clinic.cat 0000-0001-5255-3692

Publicacions destacades

Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS)

Autors:
de Velasco, Guillermo; Ruiz-Granados, Alvaro; Reig, Oscar; Massari, Francesco; Duran, Miguel Angel Climent;

(...)

del Muro, Xavier Garcia; Procopio, Giuseppe; Oudard, Stephane; Castellano, Daniel; Albiges, Laurence.

Referència: Journal Of Clinical Oncology 2020.
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer

Autors:
Marin-Aguilera, Mercedes; Reig, Oscar; Mila-Guasch, Maria; Font, Albert; Domenech, Montserrat;

(...)

Anguera, Georgia; Maroto, Pablo; Luis Fernandez, Pedro; Prat, Aleix; Mellado, Begona;.

Referència: International Journal Of Cancer 2019.
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer-types.

Autors:
Pare, L; Pascual, T; Segui, E; Teixido, C; Gonzalez-Cao, M;

(...)

Juan, M; Llovet, J M; Reguart, N; Arance, A; Prat, A.

Referència: Annals Of Oncology 2018.
Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy

Autors:
Xipell M; Victoria I; Hoffmann V; Villarreal J; García-Herrera A;

(...)

Rodas L; Blasco M; Poch E; Mellado B; Quintana L.

Referència: Oncoimmunology 2018.
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.

Autors:
Codony-Servat, Jordi; Cuatrecasas, Miriam; Asensio, Elena; Montironi, Carla; Martinez-Cardus, Anna;

(...)

Prat, Aleix; Rosell, Rafael; Garcia-Albeniz, Xabier; Camps, Jordi; Maurel, Joan.

Referència: British Journal Of Cancer 2017.
The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.

Autors:
Caballero M; Mackers P; Reig O; Buxo E; Navarrete P;

Blanch JL; Grau JJ .

Referència: Oncology 2017.
Corrigendum re: TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer [Eur Urol 2016;70:709-13]

Autors:
Reig Ò.; Marín-Aguilera M.; Carrera G.; Jiménez N.; Paré L.;

(...)

Gaba L.; Pereira M.V.; Fernández P.; Prat A.; Mellado B..

Referència: European Urology 2017.
Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study.

Autors:
Font C; Carmona-Bayonas A; Beato C; Reig Ò; Sáez A;

(...)

Marin G; Ayala F; Vicente V; Otero R; Asociación para la Investigación de la Enfermedad Tromboembólica de la región de Murcia.

Referència: European Respiratory Journal 2017.
TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer

Autors:
Reig, Oscar; Marin-Aguilera, Mercedes; Carrera, Gemma; Jimenez, Natalia; Pare, Laia;

(...)

Gaba, Lydia; Veronica Pereira, Maria; Fernandez, Pedro; Prat, Aleix; Mellado, Begona;.

Referència: European Urology 2016.
Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients

Autors:
Mellado, Begona; Jimenez, Natalia; Marin-Aguilera, Mercedes; Reig, Oscar;;

Referència: Clinical Genitourinary Cancer 2016.

Projectes destacats

Perfil molecular asociado al beneficio a la inmunoterapia en pacientes con cáncer de próstata hormonosensible: Estudios traslacionales asociados al ensayo clínico PROSTRATEGY

Investigador/a principal: Oscar Reig Torras

Finançador: Fundació Clínic per a la Recerca Biomèdica (Sede o evento); Fundación SOGUG

Durada: 01/01/2022 - 31/12/2024
Remodelación del microambiente tumoral mediante la modulación del secretoma para mejorar la respuesta a la inmunoterapia en el carcinoma renal de células claras

Finançador: Fundació Clínic per a la Recerca Biomèdica (Sede o evento); Instituto de Salud Carlos III

Durada: 01/01/2022 - 31/12/2024
Molecular and functional characterization of BAP1/PBRM1 double-mutant clear cell renal cell carcinoma.

Investigador/a principal: Oscar Reig Torras

Finançador: UT Southwestern Medical Center (Sede o evento); Fundación SEOM / Fundación CRIS contral el càncer

Durada: 01/04/2019 - 01/04/2020
Celular plasticity and immune profile and its relationship with therapeutic response in patients with metastatic prostate cancer.

Investigador/a principal: Jose Garcia Corbacho

Finançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Instituto de Salud Carlos III

Codi: PI18/00714

Durada: 01/01/2019 - 01/01/2021
Exploratory study of the role of TMPRSS2-ERG expression and associated transcriptional profile in metastatic castration-sensitive prostate cancer patients treated with hormonal therapy and taxanes

Investigador/a principal: Oscar Reig Torras

Finançador: Janssen-Cilag

Durada: 01/01/2018

Oscar Reig

Grup de recerca

Publicacions destacades

Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS)

Projectes destacats

Perfil molecular asociado al beneficio a la inmunoterapia en pacientes con cáncer de próstata hormonosensible: Estudios traslacionales asociados al ensayo clínico PROSTRATEGY

Remodelación del microambiente tumoral mediante la modulación del secretoma para mejorar la respuesta a la inmunoterapia en el carcinoma renal de células claras

Molecular and functional characterization of BAP1/PBRM1 double-mutant clear cell renal cell carcinoma.

Celular plasticity and immune profile and its relationship with therapeutic response in patients with metastatic prostate cancer.

Exploratory study of the role of TMPRSS2-ERG expression and associated transcriptional profile in metastatic castration-sensitive prostate cancer patients treated with hormonal therapy and taxanes

Subscriu-te a la Newsletter del Clínic